GB2574321A — Cannabidiol preparations

USPTO Abstract

A cannabidiol (CBD) preparation comprises greater than or equal to 98 % (w/w) CBD and less than or equal to 2 % (w/w) other cannabinoids, wherein the other cannabinoids comprise tetrahydrocannabinol (THC), cannabidiorcol (CBD-C1), cannabidivarin (CBDV) and cannabidiol-C4 (CBD-C4), and wherein the THC is present as a mixture of the trans-THC and cis-THC isomers. Also claimed is the use of such a composition as a medicament. Further claimed is the use of a composition as defined herein for use in the treatment of a neurodevelopmental disease (e.g. Parkinson’s disease, meningitis, motor neurone disease (MND)). Also claimed is the use of a composition as defined herein for the treatment of epilepsy (including Dravet syndrome, Lennox Gastaut syndrome) and schizophrenia. Preferably, the composition is isolated from a cannabis plant material (e.g. Cannabis sativa). Alternatively, the composition may use synthetically prepared cannabinoids. Preferably, the ratio of trans-THC to cis-THC is about 3.6:1 or 0.8:1.